Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 18/20 | 1.00 |
| ▸ | PDE3B | Q13370 | 1/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18737202 | 1.00 | STING1 (1.00) | STING1PDE3BPDE3A | |
| SCHEMBL12634582 | 1.00 | STING1 (1.00) | STING1PDE3BPDE3A | |
| SCHEMBL17974376 | 1.00 | STING1 (1.00) | STING1PDE3BPDE3A | |
| SCHEMBL12671632 | 1.00 | STING1 (1.00) | STING1PDE3BPDE3A | |
| SCHEMBL19954144 | 1.00 | STING1 (1.00) | STING1PDE3BPDE3A | |
| SCHEMBL24467522 | 1.00 | STING1 (1.00) | STING1PDE3BPDE3A | |
| SCHEMBL14980248 | 1.00 | STING1 (1.00) | STING1PDE3BPDE3A | |
| SCHEMBL21470181 | 1.00 | STING1 (1.00) | STING1PDE3BPDE3A | |
| SCHEMBL21498373 | 1.00 | STING1 (1.00) | STING1PDE3BPDE3A | |
| SCHEMBL17325408 | 1.00 | STING1 (1.00) | STING1PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7935814-B2 | Nitroguanosine-3′ 5′-cyclic monophosphate compound and protein kinase G activating agent | KUMAMOTO UNIVERSITY (JP) | 2011-05-03 | — | — | US | disclosed |
| US-20090215716-A1 | NITROGUANOSINE-3' 5'-CYCLIC MONOPHOSPHATE COMPOUND AND PROTEIN KINASE G ACTIVATING AGENT | KUMAMOTO UNIVERSITY (JP) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215716-A1 | NITROGUANOSINE-3' 5'-CYCLIC MONOPHOSPHATE COMPOUND AND PROTEIN KINASE G ACTIVATING AGENT | PRKG1, PRKG2, PRKAG1 | STING1 552/4885PDE3B 17/4885PDE3A 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.